RT Journal Article
SR Electronic
T1 Alzheimer’s disease: many failed trials, so where do we go from here?
JF Journal of Investigative Medicine
JO J Investig Med
FD BMJ Publishing Group Ltd
SP 1135
OP 1140
DO 10.1136/jim-2020-001297
VO 68
IS 6
A1 Allison Bethanne Reiss
A1 Amy D Glass
A1 Thomas Wisniewski
A1 Benjamin Wolozin
A1 Irving H Gomolin
A1 Aaron Pinkhasov
A1 Joshua De Leon
A1 Mark M Stecker
YR 2020
UL http://hw-f5-jim.highwire.org/content/68/6/1135.abstract
AB Alzheimer’s disease (AD) is a neurodegenerative brain disorder associated with relentlessly progressive cognitive impairment and memory loss. AD pathology proceeds for decades before cognitive deficits become clinically apparent, opening a window for preventative therapy. Imbalance of clearance and buildup of amyloid β and phosphorylated tau proteins in the central nervous system is believed to contribute to AD pathogenesis. However, multiple clinical trials of treatments aimed at averting accumulation of these proteins have yielded little success, and there is still no disease-modifying intervention. Here, we discuss current knowledge of AD pathology and treatment with an emphasis on emerging biomarkers and treatment strategies.